Assenagon Asset Management S.A. Raises Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Assenagon Asset Management S.A. lifted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 438.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 712,581 shares of the biotechnology company's stock after purchasing an additional 580,123 shares during the quarter. Assenagon Asset Management S.A. owned about 0.73% of Sarepta Therapeutics worth $45,477,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Sarepta Therapeutics by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock valued at $1,104,701,000 after purchasing an additional 117,904 shares in the last quarter. Capital International Investors boosted its position in shares of Sarepta Therapeutics by 38.9% during the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 11.1% during the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock valued at $348,368,000 after purchasing an additional 285,100 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Sarepta Therapeutics by 0.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company's stock valued at $237,901,000 after purchasing an additional 10,343 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company's stock valued at $207,538,000 after purchasing an additional 9,999 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SRPT. HC Wainwright lowered Sarepta Therapeutics from a "neutral" rating to a "sell" rating in a research report on Monday. Morgan Stanley reissued an "equal weight" rating on shares of Sarepta Therapeutics in a report on Monday. Evercore ISI downgraded Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 target price on the stock. in a report on Thursday, May 8th. UBS Group dropped their target price on Sarepta Therapeutics from $188.00 to $85.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Finally, JPMorgan Chase & Co. dropped their target price on Sarepta Therapeutics from $169.00 to $84.00 and set an "overweight" rating on the stock in a report on Tuesday, May 20th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $99.35.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock traded down $15.24 during mid-day trading on Monday, reaching $20.94. 43,592,178 shares of the stock traded hands, compared to its average volume of 1,978,766. The stock has a market capitalization of $2.06 billion, a PE ratio of 16.75 and a beta of 0.61. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 12-month low of $18.30 and a 12-month high of $173.25. The business's 50-day moving average is $45.69 and its 200-day moving average is $85.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm's revenue was up 80.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.73 EPS. As a group, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.